James R. Carroll

Boston, MA

Practice Area: Litigation

BTI Client Service All Star History
  • 2013
  • 2018
All Star


“I know I can always count on Mr. Carroll for great results.”
“He has a singular understanding of the law.”


Mr. Carroll secured important wins for the pharmaceutical industry in the U.S. Court of Appeals for the First Circuit. In May 2016, the First Circuit affirmed the dismissal with prejudice of purported securities fraud class action cases against a major Boston pharmaceutical company. In doing so, the court emphasized that the plaintiff’s use of so-called “confidential witnesses” — even when there are many of them — is no substitute for specific factual allegations of fraud. In another frequently cited First Circuit win for a pharmaceutical company, the court emphasized that drug companies have no obligation to immediately publicly disclose even very negative adverse events of a drug and that securities laws permit — indeed, require — that issuers reasonably investigate important developments prior to public disclosure. Mr. Carroll, on behalf of a German-based global pharmaceutical and chemical company, also won denial of a preliminary injunction motion seeking to enjoin a shareholder vote on whether to approve the company’s proposed $7 billion acquisition of a Massachusetts-based life science company.

Visit All Star's Firm »